All News

Another trip around the sun is quite a reason to celebrate when living with metastatic lung cancer.

March is Colorectal Cancer Awareness month and I'm happy to be part of the sea of blue that is preventing others from enduring a diagnosis of colon cancer.

Following cancer treatment, I wanted to regain some strength and stamina. Where would I start?

Genetic testing is a fascinating and provocative aspect of medicine today as it has implications for our some of our most pronounced human experiences: life, death, reproduction, parenthood, familial bonds, and one's mortality.

Inflammatory breast cancer survivor, Terry Arnold, shares her story of diagnosis and survivorship.

As a side effect of breast cancer treatment, many women develop lymphedema in the arm and upper body.

When I was diagnosed with breast cancer in 1986, no one talked about fear of recurrence and how devastating it can be in our lives.

A new study hopes to gain some clarity on what causes some breast cancer patients to feel "foggy" when receiving chemotherapy.

How I use my medical identification bracelet to keep all those advance directive, contacts and doctor info connected to me.

In the hopes of recreating the successes achieved in other solid malignancies, researchers have evaluated many types of targeted therapy for the treatment of advanced gastric cancer.

Investigational monoclonal antibodies, such as daratumumab and elotuzumab, could potentially change the role of stem cell transplantation for patients with multiple myeloma.

Josh D. Lauring, of Johns Hopkins Medicine, is interested in identifying the genetic changes that drive breast cancer growth in order to determine novel therapeutic targets for drug development and ultimately improve outcomes for patients with breast cancer.

A potential biomarker called NRP-1 may indicate longer progression-free survival with tivozanib over Avastin for patients with metastatic colorectal cancer.

According to a recent analysis of a large national database, patients with a history of breast cancer have a higher risk of developing thyroid cancer than the general population, particularly if they receive adjuvant radiation therapy.

Exploring ways technology, connectivity and health data can make a difference for cancer patients.

Cancer research groups, Apple and breast cancer organizations partner to accelerate survivorship research.

The FDA has approved Unituxin as a frontline therapy for pediatric patients with high-risk neuroblastoma who responded to prior first-line therapy.

I realized I couldn't be the only person so devastated by the effects and aftermath of cancer treatment. I decided to become a yoga teacher to help other patients and survivors.

CURE editor-in-chief and breast oncologist, Debu Tripathy, reviews the top breast cancer research highlights from 2014.

Living with advanced cancer has shifted how I view the passage of time and the growth of my children.

Kevin finally understands his place in the cancer universe.

MBCN offers advice for finding financial assistant for medical costs, daily living expenses and transportation to treatment.

Emmanuel S. Antonarakis explains data looking at AR-V7 and response to taxane therapy in men with metastatic castration-resistant prostate cancer.

The Food and Drug Administration has approved its first biosimilar, Zarxio (filgrastim-sndz), for all five of its counterpart Neupogen's authorized indications.

Treating patients with triple-negative breast cancer (TNBC) remains a challenge because these tumors do not rely on hormone receptors or HER2 amplification for tumor growth.

Results of a new study may help more lung cancer patients be eligible to participate in clinical trials.Researchers found that previously having cancer does not impact clinical outcomes in lung cancer patients.

Living in denial is sometimes not such a bad idea, especially when it comes to cancer.

The Food and Drug Administration has approved the anti–PD-1 agent Opdivo (nivolumab) for the treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). The approval comes three months ahead of the FDA's scheduled decision date.